VYNE Therapeutics (NASDAQ:VYNE) Shares Up 4.1% – Time to Buy?

VYNE Therapeutics Inc. (NASDAQ:VYNE)’s share price shot up 4.1% during trading on Thursday . The company traded as high as $1.85 and last traded at $1.78. 220,884 shares changed hands during mid-day trading, an increase of 161% from the average session volume of 84,516 shares. The stock had previously closed at $1.71.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $5.75 target price on shares of VYNE Therapeutics in a research report on Thursday, March 6th.

VYNE Therapeutics Trading Down 4.5 %

The stock has a market cap of $25.86 million, a price-to-earnings ratio of -1.98 and a beta of 1.13. The firm’s 50-day moving average is $2.30 and its two-hundred day moving average is $2.50.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.03. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.14 million. On average, analysts predict that VYNE Therapeutics Inc. will post -0.97 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Patrick G. Lepore acquired 15,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were bought at an average price of $2.92 per share, with a total value of $43,800.00. Following the completion of the purchase, the director now owns 51,472 shares of the company’s stock, valued at approximately $150,298.24. This represents a 41.13 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Acorn Capital Advisors LLC acquired a new stake in VYNE Therapeutics during the fourth quarter worth about $1,531,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of VYNE Therapeutics during the 4th quarter worth approximately $823,000. Schonfeld Strategic Advisors LLC lifted its holdings in VYNE Therapeutics by 4.8% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after acquiring an additional 8,058 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in VYNE Therapeutics during the fourth quarter worth $516,000. Finally, Bridgeway Capital Management LLC purchased a new stake in VYNE Therapeutics in the fourth quarter valued at $124,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.